The CCAAT/enhancer binding protein A (C/EBPA) is vital for establishing normal hepatic energy homeostasis and moderating hepatocellular growth. CEBPA loss-of-function mutations identified in acute myeloid leukemia patients support a tumor suppressor role for C/EBPA. Recent work showed reductions of C/EBPA levels in human hepatocellular carcinoma with the reductions correlating to tumor size and progression. We investigated the potential of reactivating c/ebpa expression during hepatic carcinogenesis to prevent tumor cell growth. We have developed a c/ebpa knock-in mouse in which a single-copy c/ebpa is regulated by one allele of the A-fetoprotein (AFP) gene promoter. The knock-in mice are physically indistinguishable from wild-type (WT) controls. However, knock-in animals were found to deposit fetal hepatic glycogen earlier than WT animals. Quantitative real-time PCR confirmed early c/ebpa expression and early glycogen synthase gene activation in knock-in fetuses. We then used diethylnitrosamine to induce hepatocellular carcinoma in our animals. Diethylnitrosamine produced half the number of hepatocellular nodules in knock-in mice as in WT mice. Immunohistochemistry showed reduced C/EBPA content in WT nodules whereas knock-in nodules stained strongly for C/EBPA. The p21 protein was examined because it mediates a C/EBPA growth arrest pathway. Nuclear p21 was absent in WT nodules whereas cytoplasmic p21 was abundant; knock-in nodules were positive for nuclear p21. Interestingly, only C/EBPA-positive nodules were positive for nuclear p21, suggesting that C/EBPA may be required to direct p21 to the cell nucleus to inhibit growth. Our data establish that controlled C/EBPA production can inhibit liver tumor growth in vivo. (Cancer Res 2005; 65(22): 10330-7) 
Introduction
The CCAAT/enhancer binding protein a (C/EBPa) belongs to the bZIP family of proteins (1, 2) and is a versatile regulatory factor. C/EBPa induces the differentiation of adipocytes and granulocytes (3) (4) (5) ; it transactivates liver genes that establish and maintain normal energy homeostasis in the neonate (6, 7) ; and C/EBPa functions as a potent inhibitor of cell division required for moderating the growth of hepatocytes (8) (9) (10) (11) .
The growth inhibitory properties of C/EBPa have been extensively studied. Early investigations identified an inverse correlation between C/EBPa gene expression and cellular proliferation in differentiated adipocytes (3, 4) . Observations in rat primary hepatocytes and partial hepatectomies revealed a >80% drop in C/EBPa transcripts as cells move into the growth phase (12) . Western blot analyses showed that cultured hepatoma cells contain f5% of the amount of C/EBPa as the normal rat liver (13) and proliferation of hepatoma cells and transformed hepatocytes was found to be inhibited by transfection with constitutively expressed C/EBPa genes (8, 9) .
Inhibition of hepatoma cell growth by C/EBPa does not require p53 or Rb (8) . Instead, C/EBPa curbs proliferation through multiple pathways involving interactions with cell cycle-related proteins (14) (15) (16) . Notably, C/EBPa increases the expression and stability of the cyclin-dependent kinase (Cdk) inhibitor p21/WAF-l/CIP-1 (14) and also directly inhibits two key Cdks, Cdk2 and Cdk4 (15) . The growth-inhibiting features of C/EBPa give it the characteristics of a tumor suppressor. Indeed, the identification of CEBPA lossof-function mutations in patients with acute myeloid leukemia has solidified the status of CEBPA as a tumor suppressor gene (17) .
Recent work revealed that C/EBPa gene expression is reduced in human hepatocellular carcinoma cells and the extent of the decrease correlates with tumor size and progression (18) . However, the question of whether or not forced expression of C/EBPa can overcome liver cancer formation in vivo has remained unanswered. Our laboratory sought to explore the potential of reactivating C/EBPa gene expression in mice during hepatic carcinogenesis to prevent tumor cell growth.
We used the promoter of the a-fetoprotein (AFP) gene to drive expression of C/EBPa because AFP is frequently up-regulated in liver cancer cells (19) . In normal development, the fetal oncoprotein AFP is synthesized primarily in the embryonic liver and yolk sac (20, 21) . AFP mRNA is detectable in the hepatic primordia, which form on the 10th day of the 21-day mouse gestation period (21) . Expression peaks in the fetal liver by the 19th day and decreases to negligible amounts after birth (20) . The prenatal AFP gene expression pattern precedes fetal c/ebpa expression in the liver by 2 to 3 days where C/EBPa mRNA is detectable on day 13, peaks near the time of birth, and then also drops after birth (22, 23) . Transcription of afp normally remains off in the adult; in contrast, c/ebpa transcription increases to a maximum again as the animal enters the adult stage of development at 6 weeks of age (7) . The increased production of C/EBPa in adulthood is consistent with the concurrent decreased rate of hepatocyte proliferation. Interestingly, during instances of coerced hepatic cell division such as in partial hepatectomies and tumorigenesis, c/ebpa transcription becomes suppressed whereas afp expression becomes reactivated (11, 12, 19, 24, 25) . This inverse relationship in gene activation between c/ebpa and afp presents an ideal condition for artificially expressing c/ebpa under the controlling elements of the AFP gene to test C/EBPa as an inhibitor of tumor growth during chemically induced carcinogenesis. Our experiments used the carcinogen diethylnitrosamine because it is well known to produce hepatocellular carcinoma in animals (26, 27) .
Here, we report the development of a C/EBPa gene knock-in mouse strain in which a single-copy C/EBPa gene is placed under the regulation of one of two endogenous alleles of the mouse AFP gene promoter. We find that c/ebpa knock-in mice deposit fetal hepatic glycogen earlier than wild-type (WT) controls and afp promoter-driven c/ebpa expression confers reduced susceptibility to diethylnitrosamine-induced hepatocarcinogenesis.
Materials and Methods
Gene targeting construct and knock-in clones. C/EBPa and AFP gene sequences were isolated from a Stratagene E phage library (Stratagene, La Jolla, CA) containing murine 129Sv genomic DNA. afp promoter (5.5 kb) and upstream sequence were spliced onto the C/EBPa gene sequence in a pBlueScript vector; a PGKneo expression cassette was placed downstream of c/ebpa; an additional 1 kb of afp sequence starting from inside intron 1 to a portion of intron 3 was added downstream of the PGKneo expression cassette to provide sufficient homologous sequence to promote efficient gene targeting into the AFP gene locus; and MC1tk was placed at the 3Vend of the cloned sequence (see Fig. 1 ). The construct (25 Ag/mL) was linearized and electroporated into AB2.2 mouse embryonic stem cells (1.8 Â 10 6 cells/ mL). Positive drug selection using G418 (active ingredient, 0.18 mg/mL; Sigma, St. Louis, MO) and negative selection using ganciclovir (2 Amol/L; Roche, Mannheim, Germany) were employed to enrich the yield of genetargeted clones. Correctly modified stem cells were identified by PCR and verified by Southern blotting. Two populations of targeted clones were then used to generate male, chimeric founder mice carrying the altered allele in their germ cells. The founders were bred to produce heterozygous gene targeted knock-in mice.
Quantitative real-time PCR analysis. The Roche Molecular Biochemicals LightCycler running the LightCycler3 Run software (version 5.10) was used to perform quantitative real-time PCR. Fluorescence was generated using the LightCycler-RNA Amplification Kit SYBR Green I (Roche). Data were collected with the LightCycler3 Data Analysis software (version 3.5.28). Real-time PCR primer sequences were as follows: C/EBPa, 5V -TGGACAA-GAACAGCAACGAGTA-3Vand 5V -GCAGTTGCCATGGCCTTGA-3Vgenerating a 238-bp product; C/EBPh, 5V -GGTTTCGGGACTTGATGCAATC-3V and 5V -CAACAACCCCGCAGGAACAT-3Vgenerating a 131-bp product; C/EBPy, 5V -CCCAAAGCTATGTGCCTTTC-3V and 5V -CTGGAGGGTTTGTGTTTTCTG-3V generating a 94-bp product; glycogen synthase (GS), 5V -CCATGAACAGCAA-GGGTTGTAA-3V and 5V -TGGAAGTGGGCAACCACATA-3V generating a 262-bp product; phosphoenolpyruvate (PEP) carboxy kinase, 5V -CGCT-GGCCAAGATTGGTATT-3Vand 5V -GGCCCAGTTGTTGACCAAA-3Vgenerating a 178-bp product; glucose-6-phosphatase, 5V -ACTGGTTCAACCTCGTCTT-CAA-3V and 5V -AACCACAAGATGACGTTCAAACA-3V generating a 264-bp product; and h-actin, 5V -ACCCACACTGTGCCCATCTA-3Vand 5V -GCCACAG-GATTCCATACCCA-3Vgenerating a 342-bp product.
Histologic analysis. Livers were fixed in 10% neutral buffered formalin, paraffin embedded, and cut into 4-Am sections. Stains used include H&E and periodic acid Schiff. Primary antibodies used were C/EBPa (14AA, Santa Cruz Biotechnology, Santa Cruz, CA) and p21 (M-19, Santa Cruz Figure 1 . A gene replacement construct was used to insert a single-copy c/ebpa sequence into the afp exon 1 locus. A, a c/ebpa probe is used to distinguish WT and knock-in (KI ) alleles. A Hin DIII site was inserted into the 3Vuntranslated region of knock-in C/EBPa gene to assist in genotype identification. Bold arrows, transcriptional directions of the C/EBPa and neomycin genes. B, on Southern blots, knock-in c/ebpa allele is identified by using a 542-bp c/ebpa fragment as a probe to detect a 3.7-kb Hin DIII fragment and a 11.0-kb Pst I fragment.
Biotechnology). Horseradish peroxidase-conjugated antirabbit antibodies (EnVision System, HRP (DAB), DakoCytomation, Carpinteria, CA) were used as secondary antibodies.
Northern blot and Western blot analyses. Northern and Western blots were quantified with the Molecular Dynamics Typhoon 8600 Variable Mode Imager. Probes for Northern blots were generated by PCR: a 542-bp C/EBPa probe was synthesized using primer sequences 5V -CACTATGCTCCCGCCC-CACTCAC-3Vand 5V -CTCCTTCCCCCAGCCGTTAG-3V ; a 299-bp AFP probe used primer sequences 5V -CACTGCTGCAACTCTTCGTA-3V and 5V -CTT-TGGACCCTCTTCTGTGA-3V ; and a 206-bp 18S probe used primer sequences 5V -CCGGCGGCTTTGGTGACTCTA-3V and 5V -CGCGCCTGCTGCCTTCCT-3V . Antibodies used in Western blot were C/EBPa (14AA, Santa Cruz Biotechnology), AFP (C-19, Santa Cruz Biotechnology), p21 (M-19, Santa Cruz Biotechnology), Cdk2 (M-2, Santa Cruz Biotechnology), Cdk4 (C-22, Santa Cruz Biotechnology), cyclin A (C-19, Santa Cruz Biotechnology), cyclin D1 (M-20, Santa Cruz Biotechnology), cyclin E (M-20, Santa Cruz Biotechnology), proliferating cell nuclear antigen (PCNA; PC10, Santa Cruz Biotechnology), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Chemicon, Temecula, CA), and h-actin (A5441, Sigma).
Carcinogenic induction. For tumor induction, diethylnitrosamine (Sigma) diluted in tricaprylin (Sigma) to a concentration of 2.5 Ag/AL was given to 12-day-old male mice by i.p. injection at 10 Ag/g body weight.
5-Bromo 2-deoxyuridine incorporation. Mice were injected via the i.p. route with 5-bromo 2-deoxyuridine (BrdUrd) solution (BD Biosciences PharMingen) at 30 Ag/g body weight. Mouse livers were collected 4 hours postinjection and fixed in 10% buffered formalin. The formalin-fixed, paraffin-embedded liver sections were immunostained with the BD PharMingen (San Diego, CA) BrdUrd In Situ Detection Kit according to the instruction of the supplier. BrdUrd-positive and BrdUrd-negative nuclei were scored (at least 1,000 nuclei per slide were scored).
Immunoprecipitation and cyclin-dependent kinase assays. Cdk2 and Cdk4 were immunoprecipitated from whole-cell protein extracts (500 Ag) for 2 hours at 4jC with saturating amounts of polyclonal Cdk2 (M-2) and Cdk4 (C-22) antibodies (Santa Cruz Biotechnology) and then with protein A-Sepharose beads (Calbiochem, San Diego, CA) for another 2 hours. For the Cdk2 kinase assay, the immunoprecipitated proteins on beads were washed thrice with 1Â PBS and resuspended in 30 AL of kinase buffer [25 mmol/L Tris-HCl (pH 7.5), 5 mmol/L MgCl 2 , and 5 mmol/L dichlorodiphenyltrichloroethane]. Five microliters of the suspension were incubated with 2 Ag histone H1 (Upstate, Charlottesville, VA) as substrate in the presence of 2 ACi of [g-32 P]ATP for 50 minutes at 37jC. The reactions were stopped on ice and samples were boiled in 5Â electrophoresis sample buffer and separated by PAGE. For the Cdk4 kinase assay, 4 Ag of Rb (Cell Signaling Technology, Beverly, MA) were used as substrate. After incubation at 30jC for 30 minutes, the reaction was stopped on ice and samples were boiled in 5Â electrophoresis sample buffer for 10 minutes. The reaction products were separated by PAGE and transferred to polyvinylidene difluoride membrane and analyzed by Western immunoblotting for phospho-Rb(Ser-795) (Cell Signaling Technology).
Results
CCAAT/enhancer binding protein A knock-in mice are phenotypically similar to wild-type mice. Because our gene knock-in strategy replaces afp exon 1 with c/ebpa sequence and a neomycin expression cassette (Fig. 1A) , homozygous knock-in mice would be fully deficient for AFP. We initially thought that AFP-deficient animals would be embryonic lethal; however, Gabant et al. (28) recently created afp knock-out mice and showed that AFP is necessary for female fertility but not required for embryonic development. We confirm Gabant's observation that AFP-deficient mice can survive to adulthood (results not shown). The majority of our experiments were conducted using heterozygous knock-in mice generated by breeding heterozygous males with WT females. Genotypes were verified by Southern hybridization (Fig. 1B) . Of 478 mice genotyped, 53% were WT and 47% were knock-in. These percentages do not deviate significantly from Mendelian expectations (Pearson m 2 test, P = 0.2). Knock-in mice are physically indistinguishable from their WT counterparts and they are fertile.
Early accumulation of CCAAT/enhancer binding protein A transcripts in knock-in livers correlates with early glycogen synthase expression and early liver glycogen storage. Because afp promoter activity is high normally only in fetal liver, we verified expression of the C/EBPa knock-in gene using quantitative real-time PCR analysis of fetal livers collected on days 13.5, 14.5, and 15.5 of gestation. As expected, C/EBPa mRNA levels in knock-in animals were already higher than in WT animals by day 13.5 of gestation ( Fig. 2A) . C/EBPa gene expression was consistently higher in knock-in animals than in WT animals throughout the time period tested. The 2-fold and 3-fold increases on days 13.5 and 15.5, respectively, are statistically significant (Fig. 2A) . Whether the excess C/EBPa transcript was due to expression of knock-in gene alone or due Figure 2 . A, quantitative real-time PCR values for C/EBPa and GS mRNAs normalized against h-actin. Mouse livers were collected on gestational days 13.5, 14.5, and 15.5 (n = 3-8 animals per sample group). *, P < 0.04 by Student's t test. B, periodic acid Schiff staining for glycogen (magenta) shows knock-in fetal livers accumulate glycogen earlier than WT fetal livers. Bar, 100 Am. C, quantitative real-time PCR values for PEP carboxy kinase (PEPCK ), glucose-6-phosphatase (G6Pase ), C/EBPh (C/EBPb ), and C/EBPy (C/EBPd ) mRNAs obtained from gestational day 15.5 livers. Values were normalized against h-actin (n = 4 WT fetal livers and 5 knock-in fetal livers). *, P < 0.05 by Student's t test.
to a combination of knock-in gene plus elevated expression of the native gene remains to be determined.
H&E staining of liver sections revealed no distinguishing morphologic features in knock-in mice as compared with WT mice (not shown). However, fetal livers from c/ebpa knock-in mice stained for glycogen at a time point earlier than WT mice. On day 14.5 of gestation, zero of four knock-in and zero of three WT animals showed hepatic glycogen deposits (Fig. 2B) . On day 15.5 of gestation, glycogen was distinctly visible in five of six knock-in livers with the sixth liver showing an abundance of glycogen; in contrast, eight of nine WT livers showed no detectable signs of glycogen deposition although trace amounts were found in the ninth liver (Fig. 2B) . By day 16.5 of gestation, four of four knock-in livers contained abundant glycogen whereas only one of three WT livers showed abundant glycogen; the remaining two WT livers showed trace amounts of glycogen (Fig. 2B) . Real-time PCR revealed GS mRNA amounts to be significantly higher in knock-in mice than in WT controls on day 14.5 of gestation ( Fig. 2A) . By day 15.5 of gestation, WT GS mRNA levels had increased to levels comparable to those of knock-in animals.
These data show that c/ebpa knock-in mice express higher levels of C/EBPa mRNA earlier than controls and this expression pattern coincides with the higher expression of glycogen synthase message and the early initiation of hepatic glycogen storage. However, two additional genes important for glucose homeostasis, PEP carboxy kinase and glucose-6-phosphatase, did not show significant deviations from normal on day 15.5 of gestation (Fig. 2C) . The glucose-6-phosphatase message was not detectable in the fetal samples but was easily detected in adult controls (not shown). In adult mice, no difference was observed in blood glucose levels (mean F SD) between WT (9.95 F 0.89 mmol/L, n = 6) and knockin animals (9.68 F 2.35 mmol/L, n = 5).
Also revealed in gestational day 15.5 livers was a 2.5-fold increase of C/EBPh message in knock-in fetuses above WT fetuses (Fig. 2C) . C/EBPy levels were not significantly different between knock-in and WT fetal livers.
Differences in CCAAT/enhancer binding protein A expression levels between knock-in and wild-type mice are highest during gestation and diminish near the time of birth. We assessed Northern and Western blots of liver samples for C/EBPa and AFP gene products (Fig. 3A) . In concurrence with our real-time PCR data, mRNA values normalized against 18S rRNA showed C/EBPa message levels to be higher in knock-in livers than in WT livers on day 19.5 of gestation, the day of birth (Newborn), and at 6 weeks of age (Adult; Table 1 ). Figure 3B shows the changes over time in the relative fold differences of C/EBPa message between knock-in and WT mice from the fetal to adult stages of development. The data indicate that whereas C/EBPa mRNA levels had increased earlier in knock-in mice, by the perinatal period, differences in c/ebpa expression between WT and knock-in mice were minimal. This likely represents a negative feedback regulation during gestation and we postulate that the native genes are downregulated to prevent overproduction of C/EBPa message. After birth, the small but statistically significantly higher level of C/EBPa mRNA in knock-in mice can reasonably be attributed to the continued low-level activity of the AFP promoter (Fig. 3B) .
Western blot analysis showed C/EBPa protein amounts to be essentially the same between WT and knock-in mice from gestational day 19.5 onwards (Table 1) , again indicating the effect of knock-in gene during the perinatal period is negligible. Differences in AFP mRNA levels between knock-in and WT mice were not statistically significant although AFP protein levels seemed to be reduced in knock-in mice (Table 1) .
CCAAT/enhancer binding protein A knock-in livers are less susceptible to hepatocellular carcinoma than wild-type livers. To investigate the potential effect of altered c/ebpa expression on liver tumorigenesis, we induced hepatocellular DNA damage using i.p. injections of diethylnitrosamine at 10 Ag/g body weight in 12-day-old male pups. Diethylnitrosamine is a carcinogenic agent which alkylates multiple sites on DNA, forming DNA adducts that lead to genetic alterations (27) . All male pups from a given litter were injected in a single session. In addition, to preserve unbiased handling of WT and knock-in mice, all injections were done before genotyping of the animals. We used juvenile mice because rapidly proliferating liver cells are required to promote the tumorigenic effects of diethylnitrosamine. At 1 year of age, both WT and knockin mice were killed and examined for the presence of liver tumors (Fig. 4A) . For every size of tumor recorded, knock-in livers displayed fewer numbers than WT livers (Fig. 4B) . The average number of surface tumors detected on knock-in livers (19.8 F 12.6; n = 10) was significantly lower than that detected on WT livers Figure 3 . A, Northern and Western blots show little difference in expression levels between WT and knock-in liver samples in the perinatal period. Tissues were collected from mice before birth (19.5 day ), within 24 hours after birth (Newborn ), and at 6 weeks of age (Adult ). 18S and GAPDH, internal loading controls. ND, not detected. B, the largest increases of C/EBPa expression levels in knock-in livers above WT livers occur during gestation. The graph indicates fold increase of C/EBPa message amounts from knock-in mice above normal WT levels after normalization to 18S. Points, mean of at least three knock-in and three WT samples each. *, P < 0.05 by Student's t test.
(41.0 F 23.3; n = 5; Student's t test, P < 0.04). Examination of liver sections revealed a histologic spectrum of hepatocellular nodules of various sizes ranging from dysplastic nodules to frank hepatocellular carcinoma (designated as ''tumor''). WT livers tended to exhibit more tumors and dysplastic nodules arising in a background of dysplasia as compared with knock-in livers where nodules seemed to arise in normal-looking liver parenchyma (Fig. 4C) . In the absence of diethylnitrosamine treatment, we have not found spontaneous development of hepatocellular nodules in either knock-in or WT animals.
The presence of CCAAT/enhancer binding protein A correlates with hepatocellular nodules containing nuclear p21 whereas the absence of CCAAT/enhancer binding protein A correlates with hepatocellular carcinomas lacking nuclear p21. Immunohistochemistry done on diethylnitrosamine-exposed livers showed positive nuclear staining for C/EBPa in the hepatocellular nodules of knock-in mice whereas similarly sized nodules in WT mice had reduced levels of nuclear C/EBPa (Fig. 5A) . Correspondingly, the nuclei of knock-in nodules were positive for p21 whereas the nuclei of nodules in WT mice showed low levels of p21 (Fig. 5B) . The quantity of p21 seems to be less in the cells in knock-in nodules as compared with WT nodules. This is likely due to p21 being consolidated in the nuclear compartment in knock-in nodules. Western blot analysis has verified higher p21 amounts in nuclei of cells from knock-in nodules than in nuclei from WT nodules (see below). The levels of nuclear p21 possibly reflect cell growth in WT nodules and growth arrest in knock-in nodules. In accord with this view, nuclei of the largest knock-in tumors as well as nuclei of tumors of WT animals also were low for C/EBPa and p21 (Fig. 5C ) reinforcing the idea that reduced C/EBPa levels correlate with tumor development (18) . Thus far, we have not observed any large tumors in either WT or knock-in animals having high amounts of nuclear C/EBPa. Moreover, we detected high levels of cytoplasmic p21 in the large knock-in tumors and WT nodules and tumors ( Fig. 5B and C) . This finding is consistent with a previous report that cytoplasmic p21 promotes cell growth (29) .
In addition, our data suggest that nuclear localization of p21 may be associated with the presence of C/EBPa because only those cells containing C/EBPa exhibit nuclear p21 (Fig. 5A-C) . This proposal is supported by the observation that p21 is absent in nuclear extracts derived from the livers of C/EBPa gene knock-out mice (30) . Western blot analysis confirms our immunohistochemistry findings that knock-in hepatocellular nodules contain higher levels of both nuclear C/EBPa and p21 than WT nodules (Fig. 5D) . Mean densitometric values expressed as a ratio to h-actin (mean F SD) show that C/EBPa levels in knock-in nodules (0.66 + 0.09, n = 2) are nearly twice as high as those in WT nodules (0.35 F 0.01, n =2; Student's t test, P < 0.05). Similarly, p21 levels in knock-in nodules (1.44 F 0.30, n = 2) are >3.5 times higher than those in WT nodules (0.40 F 0.14, n = 2; Student's t test, P < 0.05).
Cell proliferation rates are low in knock-in nodules and high in wild-type nodules. To determine the difference in growth rates between knock-in and WT nodules, BrdUrd uptake assays were done in age-matched 10-month-old mice (Fig. 6A) . In concordance with the C/EBPa and p21 results, the percent of WT nodule cells incorporating BrdUrd was nearly nine times higher than that of knock-in nodules (Fig. 6B) . The percent BrdUrd uptake by knock-in nodules was not significantly higher than that of quiescent hepatocytes from both knock-in and WT mice not treated with diethylnitrosamine. The data also show that knock-in quiescent hepatocytes grow at a rate similar to WT quiescent hepatocytes.
To verify our observations of low proliferative capacity in knockin nodules, the activities of Cdk2 and Cdk4 were examined (Fig. 7A ). Cdk2 and Cdk4 activities were found to be significantly higher in WT nodules than in both knock-in nodules and normal quiescent adult hepatocytes (Fig. 7B ). Cdk2 and Cdk4 activities in knock-in nodules were not significantly different from those in normal adult cells. Additionally, quantification by Western blot analysis of several cell cycle-related proteins was done (Fig. 7C) . Although protein levels for Cdk2, Cdk4, cyclin A, and cyclin E were higher on average in WT nodules than in knock-in nodules, these differences were not statistically significant (Fig. 7D) . However, PCNA protein levels were significantly higher in WT nodules than in knock-in nodules by 9-fold. Cyclin D1 was not detected in either WT or knock-in nodules in our assays.
Discussion
The importance of C/EBPa for establishing normal hepatic function and maintaining the nontransformed hepatic phenotype has been shown by studies of the C/EBPa knockout mouse (6, 11) . Recent work has strongly linked C/EBPa to tumor suppressor activity (17, 18) . However, attempts to arrest cell growth using C/EBPa have been done primarily in vitro and questions about the effectiveness of C/EBPa at inhibiting tumor growth in vivo have remained unanswered. As far as we are aware, we are the first to show inhibition of tumor cell growth using C/EBPa in vivo in a gene knock-in mouse model.
We chose the gene knock-in method to be sure that every cell in our system expresses the inserted C/EBPa gene in a temporal and Table 1 . Relative amounts of C/EBPa and AFP mRNAs and proteins show little difference between WT and knock-in samples spatial manner essentially identical to AFP. Our C/EBPa knock-in mice appear completely normal, showing no obvious adverse effects. Although morphologically indistinguishable from WT animals, knock-in mice nevertheless showed early glycogen synthase expression and early glycogen deposition in accordance to the AFP promoter being activated earlier than normal C/EBPa. However, the gluconeogenic enzymes, PEP carboxy kinase and glucose-6-phosphatase, were not up-regulated. This may be explained by the fact that fetal mice do not yet require independent glucose production as their energy needs are more than adequately met by the maternal blood supply. Thus, our results suggest that fetal carbohydrate metabolism is likely normal with the exception of early glycogen storage. Because C/EBPa is an important transcription factor known to transactivate many liver-specific genes, there exists the possibility of unintended and undesired gene activation in knock-in fetal livers. Although unfavorable consequences have not been detected, our observations indicate that accelerated development and maturation of knock-in liver may be a potential outcome. This hypothesis is supported by the early occurrence of glycogen accumulation (a hallmark of the mature hepatocyte) and the presence of elevated levels of C/EBPh mRNA in knock-in fetal liver. C/EBPh is known to be associated with hepatocyte proliferation (31, 32) .
Our tumor induction data indicate that knock-in mice develop half the number of nodules and tumors as WT animals. Although the time of onset of nodule/tumor formation is similar for knock-in and WT mice (microscopic foci could be detected in both starting at f6 months of age), the total number of nodules and tumors detected at 1 year of age was significantly less in knock-in mice than in WT mice. Low BrdUrd uptake and low PCNA protein amounts in knock-in nodules show that knock-in nodules do not have the high proliferative capacity of WT nodules. In addition, BrdUrd uptake assays indicate that the cell proliferation rate in knock-in nodules is comparable to that in normal WT quiescent hepatocytes. Additional evidence supporting this inference is provided by kinase assays which show that, first, Cdk2 and Cdk4 activities in knock-in nodules are lower than that of WT nodules and, second, the levels of these kinase activities in knock-in nodules are similar to those in normal quiescent adult hepatocytes. Taken together, these data suggest that knock-in nodules experienced growth arrest during their development. However, the range of nodule/tumor sizes detected in knockin mice implies that the time of arrest was not uniform, perhaps due to a variability in time of activation of the AFP promoter in cancer cells. Conspicuously, the largest tumors in knock-in mice were low for nuclear C/EBPa and p21 (Fig. 4C) . These likely represent the Figure 6 . BrdUrd incorporation rates in WT liver nodules are substantially higher than in knock-in liver nodules. A, thirty BrdUrd-positive nuclei are present in WT nodule. Arrows, three BrdUrd-positive nuclei in knock-in nodule. Dashes, outline of nodules. Bar, 100 Am. B, the graph shows the percent BrdUrd incorporation into the nuclei of cells from livers of 10-month-old knock-in animals not treated with diethylnitrosamine (KI Quiescent Hepatocytes), livers of 10-month-old WT animals not treated with diethylnitrosamine (WT Quiescent Hepatocytes ), nodules of 10-month-old knock-in animals treated with diethylnitrosamine (KI Nodules ), and nodules of 10-month-old WT animals treated with diethylnitrosamine (WT Nodules ). Columns, mean from two animals with more than 1,000 cells examined per animal. A minimum of three nodules were counted in each of knock-in and WT diethylnitrosamine-treated animals. *, P < 0.0001 by Student's t test. Figure 7 . Knock-in nodules exhibit lower levels of Cdk2 and Cdk4 activities and PCNA protein than WT nodules. A, Cdk2 and Cdk4 activities in normal adult control liver (C ), knock-in nodules (KI ), and WT nodules (WT ) as measured by phosphorylation of histone H1 and Rb, respectively. B, the graph shows Cdk2 and Cdk4 activities in WT nodules (n = 3 animals) to be higher than those in knock-in nodules (n = 3 animals) and adult normal liver (n = 1 animal). *, P < 0.05; **, P < 0.005 by Student's t test. C, Western blots comparing differences in protein levels between knock-in and WT nodules. ND, not detected. D, analysis of protein amount ratios indicates higher levels of PCNA in WT nodules than in knock-in nodules. Densitometric values were normalized against h-actin and expressed as ratios relative to the normalized knock-in values (n = 4 WT and 4 knock-in animals). *, P < 0.05 by Student's t test.
subset of tumors in which the AFP promoter escaped activation and thus escaped the growth inhibitory actions of C/EBPa. This raises the prospect of exploring additional promoters for use in conjunction with the AFP promoter to drive expression of antitumorigenic genes in a manner that more fully encompasses all liver cancer cells. Furthermore, because our current tumor induction experiments were done in heterozygous knock-in mice, the question remains on whether or not homozygous knock-in animals may be better protected against chemically induced carcinogenesis. Additionally, incorporation of an inducible promoter into a transgene construct is also a possibility for driving higher-level expression of C/EBPa.
The mechanism responsible for the arrest in nodule/tumor growth seen in our knock-in mice is likely the one elucidated by Timchenko et al. (14, 30) . C/EBPa was shown to restrain p21 degradation, allowing p21 to inhibit kinase activity and DNA synthesis. Our data are consistent with this picture as the majority of knock-in nodules were positive for both C/EBPa and nuclear p21 whereas WT nodules/tumors were absent for both. Moreover, our results show that nuclear p21 is detected only in the presence of C/EBPa. Thus, we propose that, in addition to stabilizing p21, C/EBPa may also be necessary for recruiting p21 to the cell nucleus. Whether or not the hepatocellular nodules in knock-in animals are composed of permanently growth-arrested cells is an issue yet to be resolved.
Our results show that C/EBPa gene knock-in mice possess greater resistance to diethylnitrosamine-induced liver tumorigenesis than WT mice, establishing for the first time that C/EBPa gene expression regulated by the AFP promoter is a viable strategy for inhibiting liver tumor growth in vivo. In addition, we provide evidence that early c/ebpa expression accelerates hepatic glycogen storage. Because premature human infants experience life-threatening hypoglycemia, perhaps as a result of incomplete activation of CEBPA and its target genes, creating a process which stimulates C/EBPa production to accelerate liver maturation and drive expression of critical energyrelated genes is desirable. Similarly, forced expression of the C/EBPa gene in liver tumor cells may prove useful in attenuating hepatocellular carcinoma development. Further investigations will elucidate the feasibility of applying controlled C/EBPa gene expression for the benefit of preterm infants and hepatocellular carcinoma patients.
